Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04257617 · ClinicalTrials.gov registry record · Phase 1
A Trial of ZL-1201 in Subjects With Advanced Cancer
A Phase 1 study of Advanced Cancer, sponsored by Zai Lab (Shanghai) Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 7
- Study locations
NCT04257617 is a Phase 1 study of Advanced Cancer that has completed, run by Zai Lab (Shanghai) Co.. The registered enrollment target is 37 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (85% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT04257617, a Phase 1 study of Advanced Cancer, has completed, sponsored by Zai Lab (Shanghai) Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 7
- Study locations
Study Summary
First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer
Conditions Studied
Interventions
- DRUG ZL-1201
Study Locations (7)
Arizona
- US2004 - Phoenix
Florida
- US2005 - Jacksonville
Minnesota
- US2001 - Rochester
Missouri
- US2003 - St Louis
New York
- US2002 - New York
Chongqing Municipality
- CN1003 - Chongqing
Zhejiang
- CN1002 - Hangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2023-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04257617
The ClinicalTrials.gov registry entry for NCT04257617 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Zai Lab (Shanghai) Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which ZL-1201 is the first listed.
NCT04257617 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04257617 about?
NCT04257617 is a clinical study titled "A Trial of ZL-1201 in Subjects With Advanced Cancer". First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer
What is the current status of trial NCT04257617?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2020-05-11. Estimated completion is 2023-01-19.
What conditions does trial NCT04257617 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT04257617?
The interventions under investigation include: ZL-1201 (DRUG).
Who is sponsoring clinical trial NCT04257617?
This trial is sponsored by Zai Lab (Shanghai) Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04257617 being conducted?
This trial has 7 study locations across Arizona, Florida, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.